Clinical Trial

EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis

Study acronym: EYE/SPY
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Cholangiocarcinoma remains difficult to diagnose because of the limited sensitivity of currently available endobiliary sampling techniques. Cholangioscopy-guided biopsies performed with the SPYGLASS™ DS system have improved tissue acquisition compared with conventional brushing techniques, but diagnostic sensitivity remains suboptimal, partly because of the small diameter of the dedicated biopsy forceps. The EYEMAX® cholangioscopy system has a larger working channel, potentially allowing the use of larger biopsy forceps and improved tissue acquisition. This multicenter randomized study aims to compare the diagnostic performance of EYEMAX® versus SPYGLASS™ DS for the diagnosis of malignant biliary strictures. The primary objective is to compare the positive diagnostic yield of the first four cholangioscopy-guided biopsies obtained with each system in patients with adenocarcinomatous biliary strictures.
Trial Details
NCT Number NCT07620080
Lead Sponsor David KARSENTI
Conditions Cholangiocarcinoma, Biliary Stricture
Enrollment 120 participants
Start Date 2026-09
Primary Completion 2029-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-02